Clinical trials
Malignancy clinical trials
Below are recruiting malignancy clinical trials, each written for real people, not researchers. We’re tracking 1,582 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05588141RecruitingPhase 1/Phase 2
Zotiraciclib for recurrent brain tumors with IDH mutations
This early-phase study tests zotiraciclib in people with recurring diffuse gliomas (brain tumors) that have an IDH1 or IDH2 mutation. It may help slow the tumor or shrink it by targeting a specific change in tumor biology.
Bethesda, MarylandAges 15 years+ - NCT05588154Recruiting
Donate blood and other samples to study blood cancers
This study asks healthy adults to provide blood, bone marrow (if needed), skin, saliva, and stool samples. Scientists use these samples to compare patterns related to myeloid (bone-marrow) blood cancers, which may help future research and tests.
Bethesda, MarylandAges 18–120 - NCT05588453RecruitingPhase 1/Phase 2
Immunotherapy and temozolomide for melanoma brain metastases
This early-phase study tests an immune cell treatment (natural killer cells) plus temozolomide to treat melanoma that has spread to the brain. It’s for people whose brain spots are getting worse and who are not good candidates for certain types of brain radiation.
Columbus, OhioAges 18 years+ - NCT05593107Recruiting
Check cancer with a special PET/CT scan
This trial studies how well a specific PET/CT scan using a radioactive tracer can detect or evaluate cancers. It may help doctors see where cancer is in the body more clearly.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05598879Recruiting
New heart-cancer visit registry for adults
This study is a “registry,” meaning it collects health information from adults who are getting a new heart (cardio) evaluation related to cancer. It helps doctors better understand heart risks and care needs for different cancer types and treatments.
Weston, FloridaAges 18 years+ - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Orange, CaliforniaAges 18 years+ - NCT05618041Recruiting
CAR-T treatment trial for relapsed or hard-to-treat blood cancers
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
Taiyuan, ShanxiAges 14–75 - NCT05620290RecruitingPhase 1
MR-guided ultrasound plus radiation to help skin cancer respond
This Phase 1 study tests a new way to make radiation work better using MRI-guided focused ultrasound. It focuses on improving treatment for malignant melanoma and other skin cancers, while checking safety and how patients experience treatment.
Toronto, OntarioAges 18 years+ - NCT05620329Recruiting
Pleural fluid registry for drainage in adults
This registry collects information from adults who have fluid around the lungs (pleural effusion) and need clinically indicated drainage because of infection or cancer. It helps researchers better understand these conditions and improve future care.
Chapel Hill, North CarolinaAges 18 years+ - NCT05622409Recruiting
Tissue and genetic data registry for diffuse glioma in adults
This study collects tumor tissue and basic medical information to better understand the genes involved in adult diffuse glioma. It may help future treatments by building a detailed research database and matching patients to study arms.
Kaohsiung CityAges 20 years+ - NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT05631886RecruitingPhase 1
Testing a cancer vaccine plus immune therapy for hard tumors
This early-phase trial tests whether combining a lab-made CAR-DC cancer vaccine with immune checkpoint medicines can shrink tumors that have specific genetic changes. It’s meant for people with advanced or returning (relapsed) solid tumors or certain lymphomas that match required tumor markers.
Beijing, Beijing MunicipalityAges 18–75 - NCT05635123Recruiting
Study of newly diagnosed cervical or endometrial cancer
This study follows women who are newly diagnosed with cervical or endometrial (uterine lining) cancer at a health check-up. It helps doctors learn more about these cancers and how they behave, which may improve future care.
Hangzhou, ZhejiangAges 20–75 - NCT05636384Recruiting
At-home support program for people with advanced cancer
This study tests an at-home supportive care research program for people with advanced solid tumors and their family caregivers. It may help you and your caregiver manage needs while staying at home and communicating with medical staff.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT05639972RecruitingPhase 1/Phase 2
HPV cancer trial using immune T cells made for you
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
New Brunswick, New JerseyAges 18 years+ - NCT05640700Recruiting
Study of vaginal microbiome in HPV-related early cell changes
This study looks at the vaginal “microbiome” (the normal germs and bacteria in the vagina) in people who have had abnormal Pap smear or colposcopy results related to HPV. It may help doctors understand what to monitor and how to better identify early, pre-cancer changes in the cervix.
JerusalemAges 25–70 - NCT05641961Recruiting
Mobile app for childhood cancer survivors’ long-term follow-up
This study tests a smartphone or tablet app that helps childhood cancer survivors (or their caregivers) manage long-term follow-up care. If you attend the UCSF Survivorship Clinic, the app may make it easier to understand what care you need and stay on track.
San Francisco, CaliforniaAges Any age - NCT05642455RecruitingPhase 1/Phase 2
Study of a new treatment for certain childhood cancers
This Phase 1/2 study tests a new therapy for children and young adults with specific types of cancer that have been treated with chemotherapy before. It may help by targeting cancer features in the tumor and using your immune system in a controlled way.
Palo Alto, CaliforniaAges 2–21 - NCT05648253Recruiting
Hyivy device after pelvic radiation for vaginal health
This study checks whether a special vaginal device (Hyivy) is safe and workable after pelvic radiation for certain cancers. You may be asked to use it for 12 weeks to help with vaginal changes after treatment, and you would visit the study team regularly.
Kitchener, OntarioAges 18 years+ - NCT05658640RecruitingPhase 1/Phase 2
Testing trametinib and steroid plus chemo for relapsed blood cancers
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
ViennaAges 1–21 - NCT05660369RecruitingPhase 1
CAR T-cell treatment for EGFR-mutant glioblastoma
This Phase 1 trial tests a new immune treatment made from your own immune cells to attack glioblastoma (a brain tumor), especially tumors with a specific EGFR change called EGFRvIII. It mainly focuses on safety and early signs of effectiveness, and some participants will also need surgery/biopsy and an implanted port for the treatment.
Boston, MassachusettsAges 18 years+ - NCT05665920Recruiting
Shorter radiation after breast surgery for certain node-positive cancer
This trial compares a shorter, more concentrated radiation schedule versus a standard shorter schedule after breast-conserving surgery. It looks at whether the treatment works well and is safe, especially for women whose lymph nodes also need radiation.
São Paulo, São PauloAges 18 years+ - NCT05667948Recruiting
Testing targeted treatments for thymus cancer using tumor testing
This trial studies people with thymus (thymic) cancers that have been confirmed by tissue testing. It uses tumor “molecular” (biologic/genetic) test results to guide treatment options and see how well they work.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05669430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug alone and with pembrolizumab
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignancy?
- Yes. Clin2 currently lists 1,582 recruiting malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.